{"id":"btt1023","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Infusion reactions"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"BTT1023 targets CCR2, a chemokine receptor involved in the recruitment of monocytes and other immune cells to sites of inflammation. By blocking CCR2, the drug aims to reduce inflammatory infiltration and modulate immune responses in inflammatory and autoimmune conditions. This mechanism is intended to decrease pathogenic inflammation while preserving beneficial immune function.","oneSentence":"BTT1023 is a monoclonal antibody that blocks the CC chemokine receptor 2 (CCR2) to reduce inflammatory cell recruitment and immune activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:58:53.734Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Inflammatory bowel disease"}]},"trialDetails":[{"nctId":"NCT02239211","phase":"PHASE2","title":"A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis","status":"COMPLETED","sponsor":"University of Birmingham","startDate":"2015-09-08","conditions":"Primary Sclerosing Cholangitis","enrollment":23},{"nctId":"NCT00851240","phase":"PHASE1","title":"BTT-1023 in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Biotie Therapies Corp.","startDate":"2009-02","conditions":"Rheumatoid Arthritis","enrollment":24},{"nctId":"NCT00871598","phase":"PHASE1","title":"BTT1023 in Psoriasis","status":"COMPLETED","sponsor":"Biotie Therapies Corp.","startDate":"2009-03","conditions":"Plaque Psoriasis","enrollment":26}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BTT1023","genericName":"BTT1023","companyName":"Biotie Therapies Corp.","companyId":"biotie-therapies-corp","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BTT1023 is a monoclonal antibody that blocks the CC chemokine receptor 2 (CCR2) to reduce inflammatory cell recruitment and immune activation. Used for Rheumatoid arthritis, Inflammatory bowel disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}